Drug repositioning, particularly using the antidepressant paroxetine, shows potential cardioprotective effects against doxorubicin-induced cardiotoxicity beyond its established role as an SSRI.
Does drug repositioning, specifically paroxetine, mitigate doxorubicin-induced cardiotoxicity?
Drug repositioning, particularly using paroxetine, represents a promising strategy to prevent or treat doxorubicin-induced cardiotoxicity.
Doxorubicin (DOX) is an effective drug for the treatment of solid tumors and hematological malignancies in both children and adults. The most serious side effect is doxorubicin-induced cardiotoxicity (DIC), which can lead to cardiomyopathy and irreversible and highly fatal cardiac decompensation. The precise mechanisms underlying DIC are not fully understood, and currently, no fully effective preventive or therapeutic strategies exist. Drug repositioning has emerged as a promising approach to mitigate DIC, leveraging existing safety profiles while potentially reducing the time and cost of clinical translation. In this review, we summarize current evidence on drug repurposing for DIC, with a particular focus on the antidepressant paroxetine, which shows potential cardioprotective effects beyond its established role as a selective serotonin reuptake inhibitor (SSRI).
Kosić et al. (Fri,) conducted a review in Doxorubicin-induced cardiotoxicity. Drug repositioning (paroxetine) was evaluated. Drug repositioning, particularly using the antidepressant paroxetine, shows potential cardioprotective effects against doxorubicin-induced cardiotoxicity beyond its established role as an SSRI.